International Journal of Alzheimer’s Disease

Biomarkers in Alzheimer's Disease and Lewy Body Disorders with Dementia


Publishing date
25 Jan 2013
Status
Published
Submission deadline
07 Sep 2012

Lead Editor

1Department of Psychiatry and Psychotherapy, University Hospital of Tübingen, Calwer Straße 14, 72076 Tübingen, Germany

2Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Novum 4th Floor, 141 86 Stockholm, Sweden

3Center of Neurology, Hertie Institute of Clinical Brain Research, University Hospital of Tübingen, Hoppe-Seiler-Straße 3, 727076 Tübingen; Germany

4Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA


Biomarkers in Alzheimer's Disease and Lewy Body Disorders with Dementia

Description

Alzheimer's disease (AD) and Lewy body disorders (LBDs) are the two most important reasons for neurodegenerative dementia syndromes. Due to an aging population and other demographic changes, prevalence of these neurodegenerative diseases is steadily increasing. This leads to growing social and economic burden. Basically only symptomatic treatments for these disorders are presently available. However, intensive research in these fields gives reasonable hope for neuromodulatory, neuroprotective and disease-modifying therapies to become soon a reality. The evaluation of such therapies is, however, heavily dependent on existence of reliable diagnostic and prognostic biomarkers for early detection and evaluation of the stages of the disease, defining the rate of disease progression prior to and following existing and future therapeutic interventions. Current biomarkers of these devastating neurodegenerative diseases are not sufficient for these purposes as the neurodegenerative processes start long before appearance of clinical symptoms. Candidate biomarkers for a preclinical diagnosis are strongly required. Hence, there is an urgent need for development, characterization, and improvement of such new and hopefully multifaceted biomarkers. For this special issue, we invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to develop and improve all kinds of biomarkers for these two neurodegenerative diseases. We are particularly interested in articles describing new methodological approaches and new hypothesis which would stimulate biomarker approaches in AD and LBD. However, studies investigating the validity of the existing biomarkers or combinations of them are also welcome. Potential topics include, but are not limited to:

  • Recent developments in neurochemical biomarkers
  • Recent developments in imaging biomarkers
  • Recent developments in genetic markers
  • Recent developments in multimodal approaches

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ijad/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2013
  • - Article ID 473181
  • - Editorial

Biomarkers in Alzheimer's Disease and Lewy Body Disorders with Dementia

Thomas Leyhe | Taher Darreh-Shori | ... | Walter Maetzler
  • Special Issue
  • - Volume 2012
  • - Article ID 391438
  • - Review Article

Protein Clearance Mechanisms of Alpha-Synuclein and Amyloid-Beta in Lewy Body Disorders

Michela Deleidi | Walter Maetzler
  • Special Issue
  • - Volume 2012
  • - Article ID 910757
  • - Research Article

Cognitive Profiles in Parkinson’s Disease and Their Relation to Dementia: A Data-Driven Approach

Inga Liepelt-Scarfone | Susanne Gräber | ... | Daniela Berg
  • Special Issue
  • - Volume 2012
  • - Article ID 324016
  • - Clinical Study

Elevated Angiopoietin-1 Serum Levels in Patients with Alzheimer’s Disease

Brigitte Schreitmüller | Thomas Leyhe | ... | Christoph Laske
  • Special Issue
  • - Volume 2012
  • - Article ID 437025
  • - Review Article

-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies

Kensaku Kasuga | Masatoyo Nishizawa | Takeshi Ikeuchi
  • Special Issue
  • - Volume 2012
  • - Article ID 979804
  • - Research Article

Test-Retest Reliability of a New Medial Temporal Atrophy Morphological Metric

Simon Duchesne | Fernando Valdivia | ... | Nicolas Robitaille
  • Special Issue
  • - Volume 2012
  • - Article ID 703871
  • - Research Article

The Relation between Inflammation and Neuropsychological Test Performance

Valerie H. Balldin | James R. Hall | ... | Sid E. O'Bryant
  • Special Issue
  • - Volume 2012
  • - Article ID 209409
  • - Review Article

Will Posttranslational Modifications of Brain Proteins Provide Novel Serological Markers for Dementias?

Y. Wang | M. G. Sørensen | ... | K. Henriksen
International Journal of Alzheimer’s Disease
 Journal metrics
Acceptance rate-
Submission to final decision-
Acceptance to publication-
CiteScore2.610
Impact Factor-
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.